Bristol-Myers Squibb Company (BMY) · page 7 of 16
The slide uses a bar chart to highlight the high revenue concentration of Revlimid compared to historical blockbuster drugs, and a range chart to show analyst uncertainty for Celgene's pipeline.
Shareholder letter · peer_benchmark · compare_peers · overcrowded density
Slide locked Sign in to view
Slide schematic 7/7
chart 2/2 paragraph 2/2 source-note 1/1 title 2/2
Components 7
bar-vertical bar-vertical paragraph paragraph source-note headline headline
Tools 1
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.